Medicilon assists Shanghai Institute of Biological Products' innovative ADC drug obtain clinical approval

On February 19, SIBP-A17, the second class I innovative antibody drug conjugate (ADC) independently developed by China National Pharmaceutical Group's Shanghai Institute of Biological Products, received a clinical trial approval notice from the National Medical Products Administration (NMPA).  The SIBP-A17 is intended for clinical trials in patients with advanced malignant solid tumors.

Shanghai Medicilon Inc. (Medicilon), as a partner of Shanghai Institute of Biological Products, provides preclinical research services such as pharmacokinetics and safety evaluation for the research and development of SIBP-A17.  This is another successful case of Medicilon helping the rapid implementation of research and development results in the ADC field.

Medicilon Antibody Drug Conjugate R&D Service Platform
One-Stop Service Promotes Efficient Drug Research and Development

Honest innovation drives the Shanghai Institute of Biological Products to continuously upgrade its products, and also drives Medicilon to develop a new pattern of technical services.  As one of the one-stop biopharmaceutical preclinical R&D service platforms in China, Medicilon has established an antibody drug conjugate (ADC) R&D service platform.  Through continuous technological innovation, Medicilon can provide clients with one-stop preclinical research services such as ADC payloads synthesis, ADC drug conjugation, ADC pharmacodynamics evaluation, ADC pharmacokinetics evaluation and ADC safety evaluation.

Learn more about ADC R&D Service Platform